Question 1

How does EquitAI evaluate Pediatrix Medical Group, Inc.'s (MD) valuation and Stock DNA?

Accepted Answer

Pediatrix Medical Group, Inc. (MD) trades at $29.82 with an EquitAI Valuation DNA score of 4/10 and Quality score of 10/10. The company's trailing P/E ratio is 15.9x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does Pediatrix Medical Group, Inc. (MD) operate in?

Accepted Answer

Pediatrix Medical Group, Inc. (MD) is classified under the Healthcare sector within the Medical - Care Facilities industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Medical - Care Facilities peers and broader Healthcare market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for Pediatrix Medical Group, Inc. (MD)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $26.6 for Pediatrix Medical Group, Inc. (MD), representing an implied 10.8% downside from its current trading level of $29.82 with an average rating of Hold based on 3 analyst ratings. Individual analyst price targets range from a low of $24.0 to a high of $28.0, with a median forecast of $28.0. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does MD pay dividends or capital distributions?

Accepted Answer

Pediatrix Medical Group, Inc. does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

Question 5

Who are Pediatrix Medical Group, Inc.'s (MD) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include PRVA, NUTX, PGNY, AMN. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's MD analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

MD - Pediatrix Medical Group, Inc. Stock Analysis & Valuation

Pediatrix Medical Group, Inc.

FIT ANALYSIS

Recent SEC Filings & Insights